- NCIt
- C173097
Loading cancer entity…
Loading cancer entity…
Clinical trials
70 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03493425 | Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | active not recruiting | Phase 2 | 82 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05546827 | Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07281417 | Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma | recruiting | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07156227 | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 3 | 403 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03803774 | Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02567422 | Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07522879 | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma(MRG003-SACC) | recruiting | Phase 2 | 40 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05075980 | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | active not recruiting | Phase 2 | 174 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06662058 | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | recruiting | N/A | 118 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma(PANDA) | not yet recruiting | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07652489 | Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study(SPORT-SNACC) | recruiting | — | 70 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07320508 | Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study(EIC-SNACC) | recruiting | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07563088 | SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma(SPARE-1st) | not yet recruiting | — | 200 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05925491 | Pembrolizumab in Locally Advanced Sinonasal Carcinoma(NeoPeSino) | recruiting | Phase 2 | 28 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04870762 | Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | recruiting | Phase 2 | 119 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07512466 | Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations | not yet recruiting | N/A | 25 | Assiut UniversityOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT04755855 | Prospective Sinonasal Cancer Multi-institution Study | recruiting | — | 200 | Mayo ClinicOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05483374 | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers(EURACAN) | recruiting | — | 13,600 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 3 | Apr 3, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05151588 | Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma | not yet recruiting | Phase 2 | 30 | Dr. Victor H.F. LeeOTHER | 0 | Feb 28, 2023 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials